These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8458175)

  • 21. FDA revises process for responding to drug applications.
    Lang L
    Gastroenterology; 2008 Sep; 135(3):721. PubMed ID: 18691586
    [No Abstract]   [Full Text] [Related]  

  • 22. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA aims to improve and streamline the drug development and review process.
    Drug News Perspect; 2003; 16(1):40. PubMed ID: 12739551
    [No Abstract]   [Full Text] [Related]  

  • 24. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 25. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R; Harris J; Wadhwa S; Chambers W
    Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA reform: new Senate bill. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environmental assessments and findings of no significant impact--FDA. Notice.
    Fed Regist; 1998 May; 63(95):27300-3. PubMed ID: 10179346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA notifications. Accelerated approval for raltegravir tablets.
    AIDS Alert; 2007 Dec; 22(12):143-4. PubMed ID: 18411485
    [No Abstract]   [Full Text] [Related]  

  • 35. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An FDA perspective on the drug development process.
    Woodcock J
    Food Drug Law J; 1997; 52(2):145-50. PubMed ID: 10557550
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA begins product approval initiative.
    Lewis C
    FDA Consum; 2003; 37(3):10-1. PubMed ID: 12793386
    [No Abstract]   [Full Text] [Related]  

  • 38. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA consolidates review process for new pharmaceuticals.
    FDA Consum; 2002; 36(6):2. PubMed ID: 12523280
    [No Abstract]   [Full Text] [Related]  

  • 40. 3TC receives full approval.
    Grodeck B; Vazquez E
    Posit Aware; 1997; 8(3):11. PubMed ID: 11364417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.